BioArctic

BioArctic P/B

The P/B (Price-to-Book Ratio) of BioArctic (BIOA B.ST) as of Sep 30, 2026 is 13.92. In the previous year, P/B (Price-to-Book Ratio) was 30.59 — a change of -54.50% (lower).

P/B

13.92

YoY

-54.50%

Last updated:

P/B (Price-to-Book Ratio) of BioArctic is 2026 13.92 . P/B (Price-to-Book Ratio) of BioArctic was 2025 30.59 . It decreases by -54.50% lower compared to the previous year.

The BioArctic P/B history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/B
Date
P/B
Jan 1, 2018
26.90 SEK
Jan 1, 2019
28.09 SEK
Jan 1, 2020
30.17 SEK
Jan 1, 2021
34.71 SEK
Jan 1, 2022
34.81 SEK
Jan 1, 2023
26.15 SEK
Jan 1, 2024
30.59 SEK
Jan 1, 2025
13.92 SEK
The BioArctic P/B history
YEARP/BYoY
13.92-54.50%
30.59+16.94%
26.15-24.87%
34.81+0.31%
34.71+15.04%
30.17+7.41%
28.09+4.44%
26.90-37.50%
43.03-90.45%
450.50+78.21%
252.79—
Access this data via the Eulerpool API

BioArctic Stock analysis

What does BioArctic do? BioArctic AB is a Swedish biotechnology company founded in 2003. The company is based in Stockholm and focuses on the development of innovative therapeutics for nervous system diseases such as Alzheimer's, Parkinson's, and spinal cord injuries. The company uses its expertise in biological and chemical drug research to discover and develop new therapeutic possibilities, with a focus on Amyloid-Beta production. BioArctic's business strategy is based on partnerships with pharmaceutical and biotech companies worldwide, working closely with partners to develop therapies and products that meet the needs and expectations of patients and doctors. BioArctic conducts research in three different areas: Alzheimer's, Parkinson's, and spinal cord injuries. The company works with partners such as Nutricia, Eisai, Just Biotherapeutics, Abcam, Neuropharm, AbbVie, Q-Med, Uppsala University, and the Karolinska Institute to develop treatments for these conditions. BioArctic has already brought several promising products to market, including BAN2401 for Alzheimer's and SC0806 for spinal cord injuries. Overall, BioArctic is a leading company in biological and chemical drug research, with a focus on developing new therapies and products for the benefit of patients and doctors worldwide. BioArctic is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioArctic stock

P/B (Price-to-Book Ratio) of BioArctic is 13.92 in 2026.

P/B (Price-to-Book Ratio) of BioArctic changed from 30.59 to 13.92, representing a -54.50% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of P/B (Price-to-Book Ratio) BioArctic since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Book ratio compares a company's market price to its book value. A low P/B may indicate an undervalued stock, while a high P/B could suggest overvaluation or strong growth expectations.

P/B = Stock Price / Book Value per Share

To evaluate P/B (Price-to-Book Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/B (Price-to-Book Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/B (Price-to-Book Ratio)'s BioArctic with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — BioArctic

All Key Metrics — BioArctic